Related Experiment Video
Updated: Oct 8, 2025
Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
Published on: June 13, 2019
Identification and analysis of a selective DYRK1A inhibitor
Tony Eight Lin1, Min-Wu Chao2, Wei-Chun HuangFu3
1Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan; Master Program in Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Abstract:
The dysregulation of DYRK1A is implicated in many diseases such as cancer, diabetes, and neurodegenerative diseases. Alzheimer's disease is one of the most common neurodegenerative disease and has elevated interest in DYRK1A research. Overexpression of DYRK1A has been linked to the formation of tau aggregates. Currently, an effective therapeutic treatment that targets DYRK1A is lacking. A specific small-molecule inhibitor would further our understanding of the physiological role of DYRK1A in neurodegenerative diseases and could be presented as a possible therapeutic option. In this study, we identified pharmacological interactions within the DYRK1A active site and performed a structure-based virtual screening approach to identify a selective small-molecule inhibitor. Several compounds were selected in silico for enzymatic and cellular assays, yielding a novel inhibitor. A structure-activity relationship analysis was performed to identify areas of interactions for the compounds selected in this study. When tested in vitro, reduction of DYRK1A dependent phosphorylation of tau was observed for active compounds. The active compounds also improved tau turbidity, suggesting that these compounds could alleviate aberrant tau aggregation. Testing the active compound against a panel of kinases across the kinome revealed greater selectivity towards DYRK1A. Our study demonstrates a serviceable protocol that identified a novel and selective DYRK1A inhibitor with potential for further study in tau-related pathologies.
Insights
Researchers identified a novel, selective small-molecule inhibitor for DYRK1A, a protein linked to neurodegenerative diseases like Alzheimer's. This inhibitor shows potential in reducing tau aggregation, offering a possible therapeutic avenue.
Area of Science:
- Biochemistry
- Neuroscience
- Drug Discovery
Background:
- DYRK1A dysregulation is linked to cancer, diabetes, and neurodegenerative diseases.
- Overexpression of DYRK1A is associated with tau aggregate formation in Alzheimer's disease.
- A targeted therapeutic for DYRK1A is currently unavailable.
Purpose of the Study:
- To identify a selective small-molecule inhibitor of DYRK1A.
- To investigate the potential of DYRK1A inhibitors in addressing tau pathologies.
- To understand the physiological role of DYRK1A in neurodegeneration.
Main Methods:
- Structure-based virtual screening of the DYRK1A active site.
- In silico compound selection followed by enzymatic and cellular assays.
- Structure-activity relationship analysis and kinome-wide selectivity profiling.
Main Results:
- Identification of a novel, selective DYRK1A inhibitor.
- Demonstrated reduction in DYRK1A-dependent tau phosphorylation in vitro.
- Observed improvement in tau turbidity, indicating alleviation of tau aggregation.
- Confirmed high selectivity for DYRK1A over other kinases.
Conclusions:
- A viable protocol for identifying selective DYRK1A inhibitors was established.
- The novel inhibitor shows therapeutic potential for tau-related pathologies.
- Further studies are warranted to explore the inhibitor's efficacy in neurodegenerative disease models.
